Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | PHASE3 | NOT YET_RECRUITING | 800 | — | — | Jun 15, 2026 | Sep 28, 2032 | May 13, 2026 | - | — |
PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Velzatinib | EXPERIMENTAL | - |
| Imatinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Velzatinib | DRUG | Velzatinib will be administered |
| Imatinib | DRUG | Imatinib will be administered |
Inclusion Criteria: * Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF). * Has histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable. * Has ...